ASCO News In Brief: Roche Roferon-A
Executive Summary
Roche Roferon-A: Helsinki University Hospital Phase III study of recombinant interferon alfa-2a (IFN) with vinblastine (VLB) versus vinblastine alone in 160 patients with advanced renal cell carcinoma shows a seven-month increase in median survival for the IFN/VLB arm (15.8 months v. 8.8 months). Objective response rates were 16% for IFN/VLB and 2.5% for VLB alone. Median time to progression was 3 months in the IFN/VLB arm and 2.1 months in the VLB arm. Reversible granulocytopenia was experienced by 12 of 79 patients in the IFN/VLB arm...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth